Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
17.71
+1.02 (6.11%)
At close: Mar 23, 2026, 4:00 PM EDT
17.71
0.00 (0.00%)
After-hours: Mar 23, 2026, 7:13 PM EDT
Sarepta Therapeutics Employees
Sarepta Therapeutics had 835 employees as of December 31, 2025. The number of employees decreased by 537 or -39.14% compared to the previous year.
Employees
835
Change (1Y)
-537
Growth (1Y)
-39.14%
Revenue / Employee
$2,632,619
Profits / Employee
-$854,383
Market Cap
1.86B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 835 | -537 | -39.14% |
| Dec 31, 2024 | 1,372 | 58 | 4.41% |
| Dec 31, 2023 | 1,314 | 152 | 13.08% |
| Dec 31, 2022 | 1,162 | 322 | 38.33% |
| Dec 31, 2021 | 840 | -26 | -3.00% |
| Dec 31, 2020 | 866 | 123 | 16.55% |
| Dec 31, 2019 | 743 | 244 | 48.90% |
| Dec 31, 2018 | 499 | 244 | 95.69% |
| Dec 31, 2017 | 255 | 58 | 29.44% |
| Dec 31, 2016 | 197 | -73 | -27.04% |
| Dec 31, 2015 | 270 | 66 | 32.35% |
| Dec 31, 2014 | 204 | 58 | 39.73% |
| Dec 31, 2013 | 146 | 43 | 41.75% |
| Dec 31, 2012 | 103 | 5 | 5.10% |
| Dec 31, 2011 | 98 | 0 | - |
| Dec 31, 2010 | 98 | 35 | 55.56% |
| Dec 31, 2009 | 63 | -20 | -24.10% |
| Dec 31, 2008 | 83 | -42 | -33.60% |
| Dec 31, 2007 | 125 | 8 | 6.84% |
| Dec 31, 2006 | 117 | -6 | -4.88% |
| Dec 31, 2005 | 123 | 11 | 9.82% |
| Dec 31, 2004 | 112 | 6 | 5.66% |
| Dec 31, 2003 | 106 | 17 | 19.10% |
| Dec 31, 2002 | 89 | 4 | 4.71% |
| Dec 31, 2001 | 85 | 14 | 19.72% |
| Dec 31, 2000 | 71 | 15 | 26.79% |
| Dec 31, 1999 | 56 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Ascentage Pharma Group International | 605 |
| Recursion Pharmaceuticals | 600 |
| Ocular Therapeutix | 325 |
| Zymeworks | 264 |
| Capricor Therapeutics | 231 |
| Relay Therapeutics | 192 |
| Soleno Therapeutics | 182 |
| Definium Therapeutics | 106 |
SRPT News
- 4 days ago - Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs - Benzinga
- 4 days ago - Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® - Business Wire
- 7 days ago - Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne - Business Wire
- 20 days ago - Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 24 days ago - Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program - Business Wire
- 25 days ago - Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress - Business Wire
- 25 days ago - Sarepta CEO To Jump Ship After 'Tumultuous' Year - Benzinga
- 25 days ago - Sarepta Therapeutics CEO Ingram to retire by year end - Reuters